Biomarkers of eosinophilic inflammation in asthma

Expert Review of Respiratory Medicine

Volumn 8, Issue 2, 2014, Pages 143-150

  Loutsios, Chrystalla ^a   Farahi, Neda ^a   Porter, Linsey ^a   Lok, Laurence S C ^a   Peters, A Michael ^b   Condliffe, Alison M ^a   Chilvers, Edwin R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

allergy; biomarkers; biopsy; eosinophils; inflammation; nitric oxide; radioligands; SPECT CT; sputum

Indexed keywords

BIOLOGICAL MARKER; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL GRANULE PROTEIN; IMMUNOGLOBULIN E; INTERLEUKIN 4; INTERLEUKIN 5; MEPOLIZUMAB; NITRIC OXIDE; RESLIZUMAB; TRANSCRIPTION FACTOR RUNX2;

ALLERGIC ASTHMA; ARTICLE; BREATHING PATTERN; CIRCADIAN RHYTHM; CYTOLOGY; DISEASE SEVERITY; EOSINOPHIL; EOSINOPHIL COUNT; EOSINOPHILIA; FIBEROPTIC BRONCHOSCOPY; FORCED EXPIRATORY VOLUME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LOEFFLER PNEUMONIA; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG LAVAGE; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; PEAK EXPIRATORY FLOW; RESPIRATORY TRACT INFLAMMATION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SKIN ALLERGY; SKIN TEST; SPUTUM; TRANSBRONCHIAL BIOPSY;

ASTHMA; BIOLOGICAL MARKERS; BIOPSY; BRONCHOALVEOLAR LAVAGE; BRONCHOALVEOLAR LAVAGE FLUID; EOSINOPHILS; HUMANS; INFLAMMATION MEDIATORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PULMONARY EOSINOPHILIA;

EID: 84896792476     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2014.880052     Document Type: Article

References (71)

1. Farahi N, Singh NR, Heard S, et al. Use of 111-indium-labeled autologous eosinophils to establish the in vivo kinetics of human eosinophils in healthy subjects. Blood 2012; 120(19):4068-711
2. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol 2013;13(1): 9-222
3. Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol 2004; 113(1):30-77
4. Fabre V, Beiting DP, Bliss SK, et al. Eosinophil deficiency compromises parasite survival in chronic nematode infection. J Immunol 2009:182(3): 1577-833
5. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18(5):716-255
6. Bochner BS, Busse WW. Allergy and asthma. J Allergy Clin Immunol 2005; 115(5):953-99
7. Minshall EM, Leung DY, Martin RJ, et al. Eosinophil-associated TGF-beta1 mRNA expression and airways fibrosis in bronchial asthma. Am J Respir Cell Mol Biol 1997; 17(3):326-333
8. Flood-Page P, Menzies-Gow A, Phipps S, et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J Clin Invest 2003;112(7):1029-366
9. Barnes PJ. Reactive oxygen species and airway inflammation. Free Radic Biol Med 1990;9(3):235-433
10. Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990;323(15):1033-99
11. Broide D, Gleich G, Cuomo A, et al. Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J Allergy Clin Immunol 1991;88(4):637-488
12. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med 2012; 366(6):539-511
13. Lim S, Jatakanon A, John M, et al. Effect of inhaled budesonide on lung function and airway inflammation. Assessment by various inflammatory markers in mild asthma. Am J Respir Crit Care Med 1999;159(1):22-300
14. Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med 2011;184(10):1125-322
15. Wenzel S, Ford L, Pearlman D, et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013;368:2455-666
16. Corren J, Lemanske RF, Hanania NA, et al. Lebrikizumab treatment in adults with asthma. N Engl J Med 2011;365(12): 1088-988
17. Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med 2009;360(10):985-933
18. Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 2001;108(2): 184-900
19. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med 2003;167(2): 199-2044
20. Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 2009;360:973-844
21. Leckie MJ, Brinke AT, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 2000;356(9248):2144-88
22. Lim S, Jatakanon A, Meah S, et al. Relationship between exhaled nitric oxide and mucosal eosinophilic inflammation in mild to moderately severe asthma. Thorax 2000;55(3):184-88
23. Crimi E, Spanevello A, Neri M, et al. Dissociation between airway inflammation and airway hyperresponsiveness in allergic asthma. Am J Respir Crit Care Med 1998; 157(1):4-99
24. Horváth I, Hunt J, Barnes PJ, et al. Exhaled breath condensate: methodological recommendations and unresolved questions. Eur Respir J 2005;26(3):523-488
25. Tufvesson E, Bjermer L. Methodological improvements for measuring eicosanoids and cytokines in exhaled breath condensate. Respir Med 2006;100(1):34-88
26. Szefler SJ, Wenzel S, Brown R, et al. Asthma outcomes: biomarkers. J Allergy Clin Immunol 2012;129(Suppl 3):S9-233
27. Fireman E, Shtark M, Priel IE, et al. Hydrogen peroxide in exhaled breath condensate (EBC) vs eosinophil count in induced sputum (IS) in parenchymal vs airways lung diseases. Inflammation 2007; 30(1-2):44-511
28. Dweik RA, Boggs PB, Erzurum SC, et al. American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-155
29. McNicholl DM, Stevenson M, McGarvey LP, Heaney LG. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med 2012;186(11):1102-88
30. Smith AD, Cowan JO, Brassett KP, et al. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 2005;352(21):2163-733
31. Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med 2007;176(3):231-77
32. Szefler SJ, Mitchell H, Sorkness CA, et al. Management of asthma based on exhaled nitric oxide in addition to guideline-based treatment for inner-city adolescents and young adults: a randomised controlled trial. Lancet 2008;372(9643):1065-722
33. Petsky HL, Cates CJ, Lasserson TJ, et al. A systematic review and meta-analysis: tailoring asthma treatment on eosinophilic markers (exhaled nitric oxide or sputum eosinophils). Thorax 2012;67(3):199-2088
34. Hastie AT, Moore WC, Li H, et al. Biomarker surrogates do not accurately predict sputum eosinophil and neutrophil percentages in asthmatic subjects. J Allergy Clin Immunol 2013;132(1):72-80.e122
35. Halonen M, Barbee R, Lebowitz M, Burrows B. An epidemiological study of the interrelationships of total serum immunoglobulin E, allergy skin-test reactivity, and eosinophilia. J Allergy Clin Immunol 1982;69(2):221-88
36. Sunyer J, Antó JM, Castellsagué J, et al. Total serum IgE is associated with asthma independently of specific IgE levels. Eur Respir J 1996;9(9):1880-44
37. Simpson A, Soderstrom L, Ahlstedt S, et al. IgE antibody quantification and the probability of wheeze in preschool children. J Allergy Clin Immunol 2005;116(4):744-99
38. Baldacci S, Omenaas E, Oryszczyn MP. Allergy markers in respiratory epidemiology. Eur Respir J 2001;17(4):773-900
39. Tschopp JM, Sistek D, Schindler C, et al. Current allergic asthma and rhinitis: diagnostic efficiency of three commonly used atopic markers (IgE, skin prick tests, and Phadiatop). Results from 8329 randomized adults from the SAPALDIA study. Swiss study on air pollution and lung diseases in adults. Allergy 1998;53(6): 608-133
40. Woodruff PG, Boushey HA, Dolganov GM, et al. Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids. Proc Natl Acad Sci USA 2007;104(40):15858-633
41. Jia G, Erickson RW, Choy DF, et al. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130(3):647-54.e100
42. Tefferi A, Patnaik MM, Pardanani A. Eosinophilia: secondary, clonal and idiopathic. Br J Haematol 2006;133(5): 468-922
43. Horn BR, Robin ED, Theodore J, Van Kessel A. Total eosinophil counts in the management of bronchial asthma. N Engl J Medi 1975;92(22):1152-55
44. Druilhe A, Létuvé S, Pretolani M. Glucocorticoid-induced apoptosis in human eosinophils: mechanisms of action. Apoptosis 2003;8(5):481-955
45. Massanari M, Holgate ST, Busse WW, et al. Effect of omalizumab on peripheral blood eosinophilia in allergic asthma. Respir Med 2010;104(2):188-966
46. Winkel P, Statland BE, Saunders AM, et al. Within-day physiologic variation of leukocyte types in healthy subjects as assayed by two automated leukocyte differential analyzers. Am J Clin Pathol 1981;75(5):693-7000
47. Koh GC-H, Shek LP-C, Goh DY-T, et al. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med 2007;101(4):696-7055
48. Venge P. Genomics and proteomics of the human eosinophil. In: James JL, Helen FR, editors. Eosinophils in health and disease. Elsevier; CA, USA: 2013. p. 432-422
49. Tests of Eosinophilic Airway Inflammation. In: BTS/SIGN Guideline on the Management of Asthma. A national clinical guideline. UK. 2012; p. 26.
50. Green RH, Brightling CE, McKenna S, et al. Asthma exacerbations and sputum eosinophil counts: a randomised controlled trial. Lancet 2002;360(9347):1715-211
51. Fleming L, Wilson N, Regamey N, Bush A. Use of sputum eosinophil counts to guide management in children with severe asthma. Thorax 2012;67(3):193-88
52. Woodruff PG, Khashayar R, Lazarus SC, et al. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 2001;108(5):753-88
53. Lex C, Ferreira F, Zacharasiewicz A, et al. Airway eosinophilia in children with severe asthma: predictive values of noninvasive tests. Am J Respir Crit Care Med 2006; 174(12):1286-911
54. Claman D, Boushey H, Liu J, et al. Analysis of induced sputum to examine the effects of prednisone on airway inflammation in asthmatic subjects. J Allergy Clin Immunol 1994;94(5): 861-99
55. Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 2012;185(9):1004-144
56. Wardlaw AJ, Dunnette S, Gleich GJ, et al. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma. Relationship to bronchial hyperreactivity. Am Rev Respir Dis 1998; 137(1):62-99
57. Walker C, Kaegi M, Braun P, Blaser K. Activated T cells and eosinophilia in bronchoalveolar lavages from subjects with asthma correlated with disease severity. J Allergy Clin Immunol 1991;88(6):935-422
58. Costabel U, Teschler H, Guzman J. Bronchiolitis obliterans organizing pneumonia (BOOP): the cytological and immunocytological profile of bronchoalveolar lavage. Eur Respir J 1992; 5(7):791-77
59. Allen JN, Davis WB, Pacht ER. Diagnostic significance of increased bronchoalveolar lavage fluid eosinophils. Am Rev Respir Dis 1990;142(3):642-77
60. Persson CG, Uller L. Resolution of cell-mediated airways diseases. Respir Res 2010;11(1):755
61. Rand IA Du, Blaikly J, Booton R, et al. British Thoracic Society Guideline for diagnostic flexible bronchoscopy in adults. Thorax 2013;68:i1-i444
62. Kim C-K, Callaway Z, Fletcher R, Koh YY. Eosinophil-derived neurotoxin in childhood asthma: correlation with disease severity. J Asthma 2010;47(5):568-733
63. Sorrentino S, Glitz DG, Hamann KJ, et al. Eosinophil-derived neurotoxin and human liver ribonuclease. Identity of structure and linkage of neurotoxicity to nuclease activity. J Biol Chem 1992;267(21):14859-655
64. Kulkarni NS, Hollins F, Sutcliffe A, et al. Eosinophil protein in airway macrophages: a novel biomarker of eosinophilic inflammation in patients with asthma. J Allergy Clin Immunol 2010;126(1): 61-9.e33
65. Castro M, Fain SB, Hoffman EA, et al. Lung imaging in asthmatic patients: the picture is clearer. J Allergy Clin Immunol 2011;128(3):467-788
66. Harris RS, Venegas JG, Wongviriyawong C, et al. 18F-FDG uptake rate is a biomarker of eosinophilic inflammation and airway response in asthma. J Nucl Med 2011; 52(11):1713-200
67. Hansel TT, De Vries IJ, Iff T, et al. An improved immunomagnetic procedure for the isolation of highly purified human blood eosinophils. J Immunol Methods 1991;145(1-2):105-100
68. Petersa M. Imaging inflammation: current role of labeled autologous leukocytes. J Nucl Med 1992;33(1):65-77
69. Ruparelia P, Szczepura KR, Summers C, et al. Quantification of neutrophil migration into the lungs of patients with chronic obstructive pulmonary disease. Eur J Nucl Med Mol Imaging 2011;38(5):911-199
70. Farahi N, Loutsios C, Peters AM, et al. Use of 99m Technetium-labeled eosinophils to detect active eosinophilic inflammation in man. Am J Respir Crit Care Med 2013; 188(7):880-22
71. Chrystalla L, Neda F, Charlotte S, et al. Use of radiolabelled leukocytes for drug evaluation in man. In: Moyer BR, Cheruvu NPS, Hu T, editors. Pharmaco-imaging in drug and biologics development. Springer; NY, USA: 2014. p. 215-477